8-K: PetVivo Appoints Finance Veteran Josh Ruben to Board

PetVivo Holdings, Inc. has expanded its Board of Directors to eight members with the appointment of Josh Ruben, a seasoned expert in healthcare finance and capital markets.

Summary

• PetVivo Holdings, Inc. increased its Board of Directors from seven to eight members.
• Josh Ruben was appointed as an independent member of the Board, effective October 28, 2025.
• Mr. Ruben brings extensive experience in healthcare finance, capital markets, and corporate strategy, including executing billions of dollars in M&A and securities transactions.
• He is currently the Managing Director of Life Sciences at Trinity Capital, focusing on venture lending to healthcare companies.
• His compensation will be consistent with other non-employee directors, pro-rated for his service time.

Sentiment

Score: 8

Explanation: The appointment of a highly qualified and experienced independent director with a strong background in finance, M&A, and life sciences is a positive development for corporate governance and strategic growth, indicating a strengthening of the company's leadership.

Positives

• The appointment of a highly experienced financial expert with a strong background in life sciences, M&A, and capital markets is a significant enhancement to the Board.
• Mr. Ruben's expertise is expected to be invaluable for guiding PetVivo's growth, strengthening its capital strategy, and maximizing value creation across both veterinary and emerging human applications.
• His independence ensures strong corporate governance and objective oversight.
• The addition of a director with venture lending experience could be beneficial for future financing strategies and access to capital.

Risks

• Forward-looking statements are not guarantees of future actions or performance and are subject to a number of uncertainties and risks that could significantly affect current plans.
• Risks concerning the company's business are described in detail in its Annual Report on Form 10-K for the year ended March 31, 2025, and other periodic and current reports filed with the Securities and Exchange Commission.

Future Outlook

The company aims to continue expanding its market presence and advancing its mission to deliver innovative solutions for osteoarthritis and other joint conditions in companion animals. It also plans to expand into human therapeutic markets, leveraging its core science and commercialization strategy. Proposed development and commercial timelines are subject to change.

Management Comments

• "We are honored to welcome Josh Ruben to our Board of Directors. Josh brings a wealth of experience in healthcare finance, capital markets, and corporate strategy, with a proven track record of executing multi-billion-dollar M&A and capital transactions. His deep understanding of the life sciences industry and his strategic insights into growth-stage companies will be invaluable as we continue to expand PetVivos market presence and advance our mission to deliver innovative solutions for the treatment of osteoarthritis and other joint conditions in companion animals." John Lai, CEO of PetVivo Holdings, Inc.
• "I am thrilled to join the Board of Directors of PetVivo Holdings, Inc. PetVivos innovative technology platform, exemplified by its Spryng veterinary product, stands at the intersection of animal and human health. The Company’s continued growth in the animal health sector, along with its expansion into human therapeutic markets, represents an exciting evolution of its core science and commercialization strategy. I look forward to contributing my experience in healthcare finance and life sciences to help guide PetVivos growth, strengthen its capital strategy, and maximize value creation across both veterinary and emerging human applications." Josh Ruben.

Industry Context

The appointment of a director with strong healthcare finance and life sciences expertise aligns with the broader trend of biomedical device companies seeking to strengthen their strategic and financial leadership as they navigate complex capital markets and expand into new therapeutic areas, including the growing animal health and emerging human health sectors. PetVivo's strategy of leveraging human therapies for companion animals is a common approach in the veterinary pharmaceutical and device industry, aiming for faster market entry and revenue generation.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for enhanced strategic guidance, improved capital strategy, and increased value creation due to Mr. Ruben's extensive expertise. Strengthened corporate governance through the addition of an independent director.
• Management: Gains a seasoned advisor with deep financial and industry knowledge to support growth initiatives and strategic decision-making.
• Employees: No direct immediate impact mentioned, but a stronger and more experienced board can lead to more stable and strategic company direction, potentially benefiting long-term employee prospects.

Next Steps

• Mr. Ruben will serve until the next annual meeting of shareholders and until his successor is duly elected and qualified.
• The Board may appoint Mr. Ruben to specific committees in the future.
• The company plans to continue expanding its market presence and advancing its mission in animal health.
• The company plans to expand into human therapeutic markets, leveraging its core science and commercialization strategy.

Key Dates

Recommendation

The appointment of Josh Ruben to the Board of Directors is a positive development, bringing significant financial and life sciences expertise that could strengthen PetVivo's strategic direction and capital strategy. However, as this filing primarily concerns corporate governance and not financial performance or new product milestones, it does not fundamentally alter the company's immediate operational outlook or valuation metrics. Investors should hold their positions while monitoring future strategic execution and financial results, particularly regarding the company's expansion into human therapeutic markets and capital strategy.

Keywords

PetVivo Holdings, PETV, Board of Directors, Josh Ruben, Life Sciences, Healthcare Finance, Corporate Governance, Venture Lending, Biomedical Device, Animal Health, Spryng, OsteoCushion, PRP